Where Does Rare Disease and Patient-Focus Fall into Commissioner Makary’s Priorities & the MAHA Platform for FDA? A New Ultrarare Approval Pathway & More April 21, 2025 By Dr. Naomi Lowy, Principal Drug Regulatory Expert & James E. Valentine —

https://www.thefdalawblog.com/2025/04/where-does-rare-disease-and-patient-focus-fall-into-commissioner-makarys-priorities-the-maha-platform-for-fda-a-new-ultrarare-approval-pathway-more/?utm_source=rss&utm_medium=rss&utm_campaign=where-does-rare-disease-and-patient-focus-fall-into-commissioner-makarys-priorities-the-maha-platform-for-fda-a-new-ultrarare-approval-pathway-more